Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years.

OBJECTIVE: Epidemiological studies have shown an increased risk for prostate carcinoma in men with serum IGF-I in the upper part of the age-related reference range. Recombinant human GH (rhGH) is widely used in patients with GH deficiency, usually raising the serum IGF-I levels into the normal range...

Descrizione completa

Dettagli Bibliografici
Autori principali: le Roux, C, Jenkins, P, Chew, S, Camacho-Hübner, C, Grossman, AB, Besser, G, Monson, J
Natura: Journal article
Lingua:English
Pubblicazione: 2002